0000320017-21-000043 | 10-K | XBRL Viewer | Caladrius Biosciences INC

Print Document View Excel Document

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Dec. 31, 2020	Feb. 25, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-33650
Entity Registrant Name	CALADRIUS BIOSCIENCES, INC.
Entity Central Index Key	0000320017
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-2343568
Entity Address, Address Line One	110 Allen Road, 2nd Floor
Entity Address, City or Town	Basking Ridge
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07920
City Area Code	908
Local Phone Number	842-0100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	CLBS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 27
Entity Common Stock, Shares Outstanding		59,505,261
Documents Incorporated by Reference	The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement for the 2021 Annual Meeting of Stockholders.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 16,512	$ 14,032
Marketable securities	18,061	11,125
Prepaid and other current assets	758	815
Total current assets	35,331	25,972
Property and equipment, net	57	100
Other assets	614	1,081
Total assets	36,002	27,153
Liabilities
Accounts payable	1,020	1,490
Accrued liabilities	2,486	4,486
Total current liabilities	3,506	5,976
Other long-term liabilities	254	624
Total liabilities	3,760	6,600
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2020 and December 31, 2019, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 19,389,413 and 10,528,689 shares, at December 31, 2020 and December 31, 2019, respectively; and outstanding, 19,378,333 and 10,517,609 shares, at December 31, 2020 and December 31, 2019, respectively	19	11
Additional paid-in capital	458,748	438,911
Treasury stock, at cost; 11,080 shares at December 31, 2020 and December 31, 2019 respectively	(708)	(708)
Accumulated deficit	(425,550)	(417,400)
Accumulated other comprehensive (loss) income	(13)	2
Total Caladrius Biosciences, Inc. stockholders' equity	32,496	20,816
Noncontrolling interests	(254)	(263)
Total equity	32,242	20,553
Total liabilities, non-controlling interests and equity	$ 36,002	$ 27,153

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred Stock
Preferred stock, shares authorized (shares)	20,000,000	20,000,000
Preferred stock, liquidation preference (shares)	0.001	0.001
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares designated (shares)	825,000	825,000
Preferred stock, shares issued (shares)	10,000	10,000
Preferred stock, shares outstanding (shares)	10,000	10,000
Common Stock
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	500,000,000	500,000,000
Common stock, shares, issued (shares)	19,389,413	10,528,689
Common stock, shares, outstanding (shares)	19,378,333	10,517,609
Treasury Stock
Treasury stock (shares)	11,080	11,080

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Expenses:
Research and development	$ 9,253	$ 10,797
General, and administrative	9,892	9,295
Operating expenses	19,145	20,092
Operating loss	(19,145)	(20,092)
Other income:
Other income, net	132	740
Total other income, net	132	740
Net loss before benefit from income taxes and noncontrolling interests	(19,013)	(19,352)
Benefit from income taxes	(10,872)	0
Net loss	(8,141)	(19,352)
Less - net income attributable to noncontrolling interests	9	9
Net loss attributable to Caladrius Biosciences, Inc. common shareholders	$ (8,150)	$ (19,361)
Basic and diluted loss per share:
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders (in dollars per share)	$ (0.53)	$ (1.88)
Weighted average common shares outstanding:
Basic and diluted weighted average common shares outstanding (shares)	15,440	10,325

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (8,141)	$ (19,352)
Other comprehensive loss:
Available for sale securities - net unrealized (loss) income	(15)	34
Total other comprehensive (loss) income	(15)	34
Comprehensive loss	(8,156)	(19,318)
Comprehensive income attributable to noncontrolling interests	9	9
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (8,165)	$ (19,327)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Adoption of accounting standard	Total Caladrius Biosciences, Inc. Stockholders' Equity	Total Caladrius Biosciences, Inc. Stockholders' Equity Adoption of accounting standard	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated Deficit Adoption of accounting standard	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2018					10,000	9,866,000
Beginning Balance at Dec. 31, 2018	$ 37,454	$ (62)	$ 37,726	$ (62)	$ 0	$ 10	$ 436,433	$ (32)	$ (397,977)	$ (62)	$ (708)	$ (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(19,352)		(19,361)						(19,361)			9
Unrealized gain (loss) on marketable securities	34		34					34
Share-based compensation (in shares)						94,000
Share-based compensation	1,165		1,165			$ 0	1,165
Net proceeds from issuance of common stock (in shares)						569,000
Net proceeds from issuance of common stock and warrants	1,314		1,314			$ 1	1,313
Ending Balance (in shares) at Dec. 31, 2019					10,000	10,529,000
Ending Balance at Dec. 31, 2019	20,553		20,816		$ 0	$ 11	438,911	2	(417,400)		(708)	(263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,141)		(8,150)						(8,150)			9
Unrealized gain (loss) on marketable securities	(15)		(15)					(15)
Share-based compensation (in shares)						53,000
Share-based compensation	1,117		1,117			$ 0	1,117
Net proceeds from issuance of common stock (in shares)						8,807,000
Net proceeds from issuance of common stock and warrants	18,728		18,728			$ 8	18,720
Ending Balance (in shares) at Dec. 31, 2020					10,000	19,389,000
Ending Balance at Dec. 31, 2020	$ 32,242		$ 32,496		$ 0	$ 19	$ 458,748	$ (13)	$ (425,550)		$ (708)	$ (254)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (8,141)	$ (19,352)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	1,265	1,295
Depreciation and amortization	63	65
Amortization/accretion on marketable securities	307	232
Changes in operating assets and liabilities:
Prepaid and other current assets	56	238
Other assets	466	504
Accounts payable, accrued liabilities and other liabilities	(2,839)	(1,864)
Net cash used in operating activities	(8,823)	(18,882)
Cash flows from investing activities:
Purchase of marketable securities	(34,799)	(32,938)
Sales of marketable securities	27,542	54,370
Purchases of property and equipment	(20)	0
Net cash (used in) provided by investing activities	(7,277)	21,432
Cash flows from financing activities:
Tax withholding payments on net share settlement equity awards	(148)	(130)
Net proceeds from issuance of capital stock	18,728	1,313
Net cash provided by financing activities	18,580	1,183
Net increase in cash and cash equivalents	2,480	3,733
Cash and cash equivalents at beginning of year	14,032	10,299
Cash and cash equivalents at end of year	16,512	14,032
Supplemental Disclosure of Cash Flow Information:
Interest	0	0
Taxes	$ 0	$ 0

The Business	12 Months Ended
The Business	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Business	The Business OVERVIEW Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring autologous CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company's technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication. The Company's goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for pre-dialysis patients with chronic kidney disease (“CKD”) and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the U.S. Food and Drug Administration (the “FDA”) to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). Coronavirus Considerations In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot be reasonably estimated at this time. In response to the pandemic, we have implemented work from home as well as social distancing and other hygiene policies for employees when they must be in the office. Our clinical study of HONEDRA® in Japan has experienced delays in enrollment due to the “State of Emergency” in effect in Japan for most of 2020 and re-implemented in Japan on Jan 7, 2021 and now extending through March 7, 2021 covering Tokyo and other regions in response to increased number of COVID-19 patients. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions. Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting PoliciesCash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.

Marketable Securities

The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.

Property and Equipment

The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:


Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Long-lived Assets

Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.

Research and Development Costs

Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.

To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.

New Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses, which will require companies to present assets held at amortized cost and available for sale debt securities net of the amount expected to be collected. The guidance requires the measurement of expected credit losses to be based on relevant information from past events, including historical experiences, current conditions and reasonable and supportable forecasts that affect collectability. The guidance was effective for fiscal years and interim periods beginning after December 15, 2019 and early adoption was permitted. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In July 2019, the FASB issued ASU 2019-07, "Codification Updates to SEC Sections", to codify the SEC releases that clarify and improve the disclosure and presentation requirements of a variety of codification topics, thereby eliminating certain disclosure requirements that were redundant, duplicative, overlapping, outdated, or superseded. For public companies, the amendments are effective upon issuance. The Company determined that the adoption of this new accounting guidance did not have a material impact on its consolidated financial statements and footnote disclosures.

In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance will not have a material impact on its financial statements and footnote disclosures.

Available-for-Sale-Securities

12 Months Ended

Dec. 31, 2020

Investments, Debt and Equity Securities [Abstract]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents in the Company's Consolidated Balance Sheets (in thousands):


	December 31, 2020								December 31, 2019
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Corporate debt securities	$	8,406	$	—	$	(7)	$	8,399	$	11,673	$	3	$	(1)	$	11,675
Money market funds	7,591		—				7,591		11,093						11,093
Municipal debt securities	$	14,753	—		$	(6)	14,747		$	—	—		$	—	—

Total	$	30,750	$	—	$	(13)	$	30,737	$	22,766	$	3	$	(1)	$	22,768

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):


	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	12,676	$	11,643
Marketable securities	18,061		11,125
Total	$	30,737	$	22,768

The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):


	December 31, 2020				December 31, 2019
	Amortized Cost		Estimated Fair Value		Amortized Cost		Estimated Fair Value
Less than one year	$	30,750	$	30,737	$	22,766	$	22,768
Greater than one year	—		—		—		—
Total	$	30,750	$	30,737	$	22,766	$	22,768

Property and Equipment

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consisted of the following (in thousands):


	December 31,
	2020		2019
Furniture and fixtures	$	26	$	26
Computer equipment	254		247
Leasehold improvements	90		76
Property and equipment, gross	370		349
Accumulated depreciation	(313)		(249)
Property and equipment, net	$	57	$	100

The Company’s results included depreciation expense of approximately $0.1 million and $0.1 million for the years ended December 31, 2020 and 2019, respectively.

Loss Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Loss Per Share

For the years ended December 31, 2020 and 2019, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2020 and 2019, the Company excluded the following potentially dilutive securities (in thousands):


	December 31,
	2020	2019
Stock Options	964	1,044
Warrants	2,638	30
Restricted Stock Units	340	118

Fair Value Measurements

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2020 and December 31, 2019 were as follows (in thousands):


	December 31, 2020								December 31, 2019
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	18,061	$	—	$	18,061	$	—	$	11,125	$	—	$	11,125
	$	—	$	18,061	$	—	$	18,061	$	—	$	11,125	$	—	$	11,125

The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value at December 31, 2020 and December 31, 2019, due to the short maturity nature of these items.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accrued Liabilities

12 Months Ended

Dec. 31, 2020

Accrued Liabilities [Abstract]

Accrued Liabilities

Accrued liabilities were as follow (in thousands):


	December 31,
	2020		2019
Salaries, employee benefits and related taxes	$	1,716	$	1,834
Operating lease liabilities - current	370		354
CIRM upfront funding - current	—		1,600
Other	400		698
	$	2,486	$	4,486

Operating Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Operating Leases

The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for two offices with terms that expire in 2022 and 2023. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments since most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):


	December 31, 2020		December 31, 2019
Right-of Use Assets:
Other assets	$	574	906
Total Right-of-Use Asset	$	574	906

Operating Lease Liabilities:
Accrued liabilities	$	370	$	353
Other long-term liabilities	254		624
Total Operating Lease Liabilities	$	624	$	977

As of December 31, 2020, the weighted average remaining lease term for our operating leases was 1.83 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of December 31, 2020 were as follows (in thousands):


Years ended	Operating Leases
2021	$	414
2022	239
2023	26
Total lease payments	679
Less: Amounts representing interest	(55)
Present value of lease liabilities	$	624

Stockholders' Equity

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Stockholders' Equity

Equity Plans

The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company's board of directors (collectively, "Participants"). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the "Committee"). The incentive plan currently used by the Company is the 2018 Equity Incentive Compensation Plan (the "2018 Plan"), which was adopted by the stockholders of the Company in June 2018, and subsequently increased by the stockholders of the Company in June of 2020 with 2,500,000 shares authorized for issuance thereunder, plus any shares awarded under the 2015 Equity Compensation Plan (the "2015 Plan") or the Amended and Restated 2009 Equity Compensation Plan (the "2009 Plan") that are not issued due to their subsequent forfeiture, cancellation, or other settlement thereof. Concurrent with the adoption of the 2018 Plan, no future awards will occur under the 2015 Plan or the 2009 Plan. The awards that may be made under the 2018 Plan include: (a) incentive stock options and nonqualified stock options, (b) shares of restricted stock, (c) restricted stock units, and (d) other kinds of equity-based compensation awards. All stock options under the 2015 Plan and 2009 Plan were granted and the 2018 Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a nonemployee, employee or director of the Company. As of December 31, 2020, there

were 1,376,030 shares available for future grants under the 2018 Plan. No additional awards may be made under the 2015 Plan or the 2009 Plan.

The Company adopted an employee stock purchase plan effective January 1, 2013 and authorized 50,000 shares under the plan (the "2012 ESPP"). The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's common stock on the Exercise Date of such Offering Period, whichever is lower. In May 2017, the Company's stockholders approved an amendment and restatement to the 2012 ESPP (the "2017 ESPP") in order to effect an increase of authorized shares from 50,000 to 100,000. In June 2018, the Company's stockholders approved an amendment to the 2017 ESPP (the " Amended 2017 ESPP") in order to effect an increase of authorized shares from 100,000 to 500,000. During the year ended December 31, 2020, 32,137 shares were issued under the Amended 2017 ESPP. At December 31, 2020, the Company had 347,709 shares of the Company's common stock available for future grant in connection with this plan.

Equity Issuances

Purchase Agreement

In March 2019, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the “Offering”). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.

Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1,000,000 (the “Initial Purchase”) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park’s obligation under any single such purchase will not exceed $2,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a “Regular Purchase”). If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an “accelerated purchase” to purchase an additional amount of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the total number of shares of the Company’s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.

The Company controls the timing and amount of any sales of its common stock to Lincoln Park. There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.

The Purchase Agreement does not limit the Company’s ability to raise capital from other sources at the Company’s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.

As of December 31, 2020, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.

Common Stock Sales Agreement

In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright & Co., LLC ("HCW") as sales agent, which was subsequently amended in August 2018 (the "Sales Agreement"), in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an

aggregate offering price of not more than $25.0 million. In March 2019, subsequent to the filing of the Company's 2018 Form 10-K, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $52.8 million. Pursuant to General Instruction I.B.6 of Form S-3, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0 million at the time of its 2018 Form 10-K filing, the aggregate amount of securities that the Company was permitted to offer and sell at such time was reduced to $17.6 million (or a maximum of 4.8 million shares), which was equal to one-third of the aggregate market value of the Company's common stock held by non-affiliates at such time.

Subject to the terms and conditions of the Sales Agreement, HCW will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon the Company's instructions, including any price, time or size limits specified by the Company. The Company has provided HCW with customary indemnification rights, and HCW will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. The Company has no obligation to sell any of the shares and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement. The Sales Agreement will terminate upon the sale of all of the shares under the Sales Agreement unless terminated earlier by either party as permitted under the Sales Agreement.

During the year-ended December 31, 2020, the Company issued 3,558,778 shares of common stock under the Sales Agreement for net proceeds of $8.5 million. As of year-ended December 31, 2020, the Company issued 3,784,912 shares of common stock under the Sales Agreement for net proceeds of $9.5 million since inception.

On February 12, 2021, we suspended the use of the at-the-market transactions facility (the “ATM”) and terminated the continuous offering pursuant to Sales Agreement entered into in February 2018 with HCW. We will no longer make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission.

Registered Direct Offerings

In April 2020, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with certain investors (the “April Purchasers”). Pursuant to the terms of the April Purchase Agreement, the Company agreed to sell to the Purchasers an aggregate of 2,162,166 shares of its common stock at a purchase price equal to $2.3125 per share. In a concurrent private placement, the Company issued to the April Purchasers warrants to purchase an aggregate of 1,081,083 shares of its common stock. In connection with the registered direct offering and concurrent private placement, the Company received gross proceeds of $5.0 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.2500 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.

In May 2020, the Company entered into a securities purchase agreement (the “May Purchase Agreement”) with certain investors (the “May Purchasers”). Pursuant to the terms of the May Purchase Agreement, the Company agreed to sell to the May Purchasers an aggregate of 2,084,850 shares of its common stock at a purchase price equal to $2.0625 per share. In a concurrent private placement, the Company issued to the Purchasers warrants to purchase an aggregate of 1,042,425 shares of its common stock. In connection with the registered direct offering and concurrent private placement, the Company received gross proceeds of $4.3 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.0625 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.

Private Placement

On July 10, 2020, the Company entered into a securities purchase agreement (the “Private Placement”) with certain investors (the “Private Placement Purchasers”). Pursuant to the terms of the Private Placement, the Company agreed to sell to the Private Placement Purchasers an aggregate of 969,694 shares of its common stock at a purchase price equal to $2.0625 per share, along with warrants to purchase an aggregate of 484,847 shares of its common stock. In connection with the Private Placement, the Company received gross proceeds of $2.0 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.0625 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2020:


	Stock Options						Warrants
	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2019	1,044,417	$	18.31	6.06	$	—	30,000	$	5.89	3.19	$	—

Changes during the Year:
Granted	248,176	$	3.20				2,608,355	$	2.14
Exercised	—	$	—				—	$	—
Forfeited	(86,251)	$	3.83				—	$	—
Expired	(242,642)	$	22.57				—	$	—
Outstanding at December 31, 2020	963,700	$	14.64	5.86	$	—	2,638,355	$	2.18	4.98	$	—
Vested at December 31, 2020 or expected to vest in the future	949,200	$	14.81	5.82	$	—	2,638,355	$	2.18	4.98	$	—
Exercisable at December 31, 2020	714,426	$	18.42	4.93	$	—	2,638,355	$	2.18	4.98	$	—

Restricted Stock

During the years ended December 31, 2020 and 2019, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	2020		2019
Number of Restricted Stock Issued	156,184		123,564
Value of Restricted Stock Issued	$	512.3	$	611.6

The weighted average estimated fair value of restricted stock issued for services in the years ended December 31, 2020 and 2019 was $3.28 and $4.95 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between one to four years.

Restricted Stock Units

During the years ended December 31, 2020 and 2019, the Company issued restricted stock units for services as follows ($ in thousands, except share data):



	2020		2019
Number of Restricted Stock Units Issued	325,853		184,454
Value of Restricted Stock Units Issued	$	863.0	$	908.6

The weighted average estimated fair value of restricted stock units issued for services in the years ended December 31, 2020 and 2019 was $2.65 and $4.93 per share, respectively. The fair value of the restricted stock units was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.

Share-Based Compensation

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

Share-based Compensation

The Company utilizes share-based compensation in the form of stock options and restricted stock. The following table summarizes the components of share-based compensation expense for the years ended December 31, 2020 and 2019 ($ in thousands):


	Year Ended December 31,
	2020		2019
Research and development	$	179	$	274
General and administrative	1,086		1,021

Total share-based compensation expense	$	1,265	$	1,295

Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2020 were as follows ($ in thousands):


	Stock Options		Restricted Stock Units		Restricted Stock
Unrecognized compensation cost	$	356	$	244	$	308
Expected weighted-average period in years of compensation cost to be recognized	1.61		2.46		1.65

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2020 and 2019 were as follows ($ in thousands):


	Stock Options
	Year Ended December 31,
	2020		2019
Total fair value of shares vested	$	536	$	398
Weighted average estimated fair value of shares granted	2.11		3.18

Valuation Assumptions

The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees.

The range of assumptions made in calculating the fair values of stock options was as follow:


	Stock Options
	Year Ended December 31,
	2020	2019
Expected term - minimum (in years)	6	6
Expected term - maximum (in years)	6	6
Expected volatility - minimum	75%	74%
Expected volatility - maximum	79%	74%
Weighted Average volatility	75%	74%
Expected dividend yield	—	—
Risk-free interest rate - minimum	0.40%	2.35%
Risk-free interest rate - maximum	1.71%	2.62%

Research Funding	12 Months Ended
Research Funding	Dec. 31, 2020
Research and Development [Abstract]
Research Funding	Research FundingCalifornia Institute of Regenerative Medicine Grant AwardIn February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded the Company funds of up to $12.2 million to support the T-Rex Study. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $8.6 million, of which $8.2 million has been received through the grant project period completion. The Company received $5.7 million in initial funding in May 2017, a $1.9 million milestone payment in December 2017, a $0.3 million progress payment in March 2018, and a $0.2 million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $46 thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the year ended December 31, 2020 and December 31, 2019, the Company amortized and recognized $1.6 million and $2.7 million in credits, respectively, in research and development related to CIRM funds received.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):


	Years Ended December 31,
Pre-tax book income	2020		2019
United States	$	(19,013)	$	(19,352)
	$	(19,013)	$	(19,352)

The provision (benefit) from income taxes was as follows ($ in thousands):


	Years Ended December 31,
	2020		2019
Current
U.S. Federal	$	—	$	—
State and local	—		—
	$	—	$	—

Deferred
U.S. Federal	$	—	$	—
State and local	(10,872)		—
	$	(10,872)	$	—

Total
U.S. Federal	$	—	$	—
State and local	(10,872)		—
	$	(10,872)	$	—

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes as a result of the following ($ in thousands):


	Years Ended December 31,
	2020		2019
U.S. Federal benefit at statutory rate	$	(3,993)	$	(4,064)
State and local (benefit) / expense net of U.S. federal tax	—		—
Permanent non deductible expenses for U.S. taxes	5		14
AMT credit benefit	—		—
Change in state deferred	5,122		(4,720)
Return to actual	—		(17)
Other true ups	387		1,941
Effect of change in deferred tax rate	—		—
Sale of New Jersey State NOL's	(10,872)		—
Valuation allowance for deferred tax assets	(1,521)		6,846
Tax provision (benefit)	$	(10,872)	$	—

Deferred income taxes at December 31, 2020 and 2019 consist of the following ($ in thousands):


	December 31,
	2020		2019
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	68,286	$	70,747
CIRM funding	—		336

Right of use liability	176		205
Share-based compensation	5,025		3,584
Intangibles	131		141




Accumulated depreciation	19		9
Accrued payroll	167		121

Other	526		737
Deferred tax assets	74,330		75,880

Deferred Tax Liabilities:
Right of use asset	$	(161)	$	(190)

Deferred tax liabilities	(161)		(190)
	74,169		75,690
Valuation allowance	(74,169)		(75,690)
Net deferred tax asset	$	—	$	—

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2020, and 2019, the Company had approximately $264 million and $246 million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. As of December 31, 2020 and 2019, the Company had State NOLs available in New Jersey of $99 million and $187 million, respectively, California of $70 million and $70 million, respectively, and New York City of $13 million and $13 million, respectively, to offset future taxable income expiring from 2030 through 2040. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.

The Company performed an analysis and determined that they have had ownership change of greater than 50% over a 3-year testing period. The last ownership change was determined to be on June 3, 2015. Based on a market capitalization of $125 million and using an applicable federal rate of 2.5% the annual limitation would be approximately $3.0 million. Post change losses from June 3, 2015 would not be subject to 382 limitations.

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of December 31, 2020, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

For years prior to 2017 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing.

In December 2019, the Company received preliminary approval from the New Jersey Economic Development Authority ("NJEDA") to participate in the Technology Business Tax Certificate Transfer Program (the "Program"). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses ("NJ NOLs") to unrelated profitable corporations. On April 21, 2020, the Company received final approval from NJEDA to sell $11.5 million of its NJ NOLs, which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $10.9 million. The net proceeds have been recorded as a benefit from income taxes in the consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Contingencies	12 Months Ended
Contingencies	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	ContingenciesFrom time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Registered Direct Offerings On February 12, 2021, we entered into a Securities Purchase Agreement (the “Institutional Purchase Agreement”) with certain institutional investors (the “Institutional Purchasers”). Pursuant to the terms of the Institutional Purchase Agreement, we sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of our common stock and warrants to purchase an aggregate of 12,453,067 shares of our common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, we entered into a Securities Purchase Agreement (the “Additional Purchase Agreement”) with certain accredited investors (the “Additional Purchasers”). Pursuant to the terms of the Additional Purchase Agreement, we sold to the Additional Purchasers an aggregate of 1,632,652 shares of our common stock and warrants to purchase an aggregate of 816,326 shares of our common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. The closing of the offerings occurred on February 17, 2021. In connection with the registered direct offerings, we received net proceeds of approximately $60.7 million. Sales Pursuant to Common Stock Sales Agreement On February 12, 2021, we suspended the use of the at-the-market transactions facility (the “ATM”) and terminated the continuous offering pursuant to the Common Stock Sales Agreement (“Sales Agreement”) entered into in February 2018 with H.C. Wainwright & Co., LLC (“HCW”). In accordance with the terms of the Sales Agreement, we could offer and sell shares of our common stock having an aggregate offering price of up to $25.0 million from time to time through HCW pursuant to the ATM program. As of February 12, 2021, we had sold an aggregate of 3,784,912 shares of our common stock pursuant to the Sales Agreement for aggregate gross proceeds of $9.5 million. We will no longer make any sales of our common stock pursuant to the Sales Agreement unless and until a new prospectus supplement is filed with the Securities and Exchange Commission. Private Placement Offering On January 21, 2021, the Company entered into a securities purchase agreement (the “January Private Placement”) with certain investors (the “January Purchasers”). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of 12,500,000 shares of its common stock at a purchase price equal to $2.00 per share, along with warrants to purchase an aggregate of 6,250,000 shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $25.0 million. Each warrant is exercisable for one share of common stock and features an exercise price equal to $2.90 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date. Warrant Exercises Subsequent to December 31, 2020 the company issued 801,148 shares of common stock for net proceeds of $1.8 million in connection with warrant exercises associated with the April Purchase Agreement and May Purchase Agreement.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Cash and Cash Equivalents

Cash and Cash EquivalentsCash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

Marketable Securities

Property and Equipment


Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Long-lived Assets

Share-Based Compensation

Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.

Treasury Stock

Research and Development Costs

New Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of Property and Equipment

The estimated useful lives of property and equipment are as follows:


Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Property and equipment consisted of the following (in thousands):


	December 31,
	2020		2019
Furniture and fixtures	$	26	$	26
Computer equipment	254		247
Leasehold improvements	90		76
Property and equipment, gross	370		349
Accumulated depreciation	(313)		(249)
Property and equipment, net	$	57	$	100

Available-for-Sale-Securities (Tables)

12 Months Ended

Dec. 31, 2020

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-Sale Securities Reconciliation

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents in the Company's Consolidated Balance Sheets (in thousands):


	December 31, 2020								December 31, 2019
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Corporate debt securities	$	8,406	$	—	$	(7)	$	8,399	$	11,673	$	3	$	(1)	$	11,675
Money market funds	7,591		—				7,591		11,093						11,093
Municipal debt securities	$	14,753	—		$	(6)	14,747		$	—	—		$	—	—

Total	$	30,750	$	—	$	(13)	$	30,737	$	22,766	$	3	$	(1)	$	22,768

Schedule of Marketable Securities


	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	12,676	$	11,643
Marketable securities	18,061		11,125
Total	$	30,737	$	22,768

Schedule of Available-for-Sale Securities by Contractual Maturity

The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):


	December 31, 2020				December 31, 2019
	Amortized Cost		Estimated Fair Value		Amortized Cost		Estimated Fair Value
Less than one year	$	30,750	$	30,737	$	22,766	$	22,768
Greater than one year	—		—		—		—
Total	$	30,750	$	30,737	$	22,766	$	22,768

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

The estimated useful lives of property and equipment are as follows:


Furniture and fixtures			10 years
Computer equipment			3 years
Software			3 years
Leasehold improvements			Life of lease

Property and equipment consisted of the following (in thousands):


	December 31,
	2020		2019
Furniture and fixtures	$	26	$	26
Computer equipment	254		247
Leasehold improvements	90		76
Property and equipment, gross	370		349
Accumulated depreciation	(313)		(249)
Property and equipment, net	$	57	$	100

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share

At December 31, 2020 and 2019, the Company excluded the following potentially dilutive securities (in thousands):


	December 31,
	2020	2019
Stock Options	964	1,044
Warrants	2,638	30
Restricted Stock Units	340	118

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets Measured on Recurring Basis

The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2020 and December 31, 2019 were as follows (in thousands):


	December 31, 2020								December 31, 2019
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	18,061	$	—	$	18,061	$	—	$	11,125	$	—	$	11,125
	$	—	$	18,061	$	—	$	18,061	$	—	$	11,125	$	—	$	11,125

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2020

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities were as follow (in thousands):


	December 31,
	2020		2019
Salaries, employee benefits and related taxes	$	1,716	$	1,834
Operating lease liabilities - current	370		354
CIRM upfront funding - current	—		1,600
Other	400		698
	$	2,486	$	4,486

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet

Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):


	December 31, 2020		December 31, 2019
Right-of Use Assets:
Other assets	$	574	906
Total Right-of-Use Asset	$	574	906

Operating Lease Liabilities:
Accrued liabilities	$	370	$	353
Other long-term liabilities	254		624
Total Operating Lease Liabilities	$	624	$	977

Schedule of Future Minimum Lease Payments Under Lease Agreements

Future minimum lease payments under the lease agreements as of December 31, 2020 were as follows (in thousands):


Years ended	Operating Leases
2021	$	414
2022	239
2023	26
Total lease payments	679
Less: Amounts representing interest	(55)
Present value of lease liabilities	$	624

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Schedule of Stock Options and Warrants Activity

The following table summarizes the activity for stock options and warrants for the year ended December 31, 2020:


	Stock Options						Warrants
	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2019	1,044,417	$	18.31	6.06	$	—	30,000	$	5.89	3.19	$	—

Changes during the Year:
Granted	248,176	$	3.20				2,608,355	$	2.14
Exercised	—	$	—				—	$	—
Forfeited	(86,251)	$	3.83				—	$	—
Expired	(242,642)	$	22.57				—	$	—
Outstanding at December 31, 2020	963,700	$	14.64	5.86	$	—	2,638,355	$	2.18	4.98	$	—
Vested at December 31, 2020 or expected to vest in the future	949,200	$	14.81	5.82	$	—	2,638,355	$	2.18	4.98	$	—
Exercisable at December 31, 2020	714,426	$	18.42	4.93	$	—	2,638,355	$	2.18	4.98	$	—

Schedule of Restricted Stock

During the years ended December 31, 2020 and 2019, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	2020		2019
Number of Restricted Stock Issued	156,184		123,564
Value of Restricted Stock Issued	$	512.3	$	611.6

Schedule of Restricted Stock Units

During the years ended December 31, 2020 and 2019, the Company issued restricted stock units for services as follows ($ in thousands, except share data):



	2020		2019
Number of Restricted Stock Units Issued	325,853		184,454
Value of Restricted Stock Units Issued	$	863.0	$	908.6

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation Expense

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2020 and 2019 ($ in thousands):


	Year Ended December 31,
	2020		2019
Research and development	$	179	$	274
General and administrative	1,086		1,021

Total share-based compensation expense	$	1,265	$	1,295


	Stock Options		Restricted Stock Units		Restricted Stock
Unrecognized compensation cost	$	356	$	244	$	308
Expected weighted-average period in years of compensation cost to be recognized	1.61		2.46		1.65

Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Values of Shares Granted

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December 31, 2020 and 2019 were as follows ($ in thousands):


	Stock Options
	Year Ended December 31,
	2020		2019
Total fair value of shares vested	$	536	$	398
Weighted average estimated fair value of shares granted	2.11		3.18

Schedule of Assumptions in Calculating Fair Values of Stock Options

The range of assumptions made in calculating the fair values of stock options was as follow:


	Stock Options
	Year Ended December 31,
	2020	2019
Expected term - minimum (in years)	6	6
Expected term - maximum (in years)	6	6
Expected volatility - minimum	75%	74%
Expected volatility - maximum	79%	74%
Weighted Average volatility	75%	74%
Expected dividend yield	—	—
Risk-free interest rate - minimum	0.40%	2.35%
Risk-free interest rate - maximum	1.71%	2.62%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes Based on Loss from Operations

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):


	Years Ended December 31,
Pre-tax book income	2020		2019
United States	$	(19,013)	$	(19,352)
	$	(19,013)	$	(19,352)

Schedule of Benefit from Income Taxes

The provision (benefit) from income taxes was as follows ($ in thousands):


	Years Ended December 31,
	2020		2019
Current
U.S. Federal	$	—	$	—
State and local	—		—
	$	—	$	—

Deferred
U.S. Federal	$	—	$	—
State and local	(10,872)		—
	$	(10,872)	$	—

Total
U.S. Federal	$	—	$	—
State and local	(10,872)		—
	$	(10,872)	$	—

Schedule of Reconciliation of Effective Income Taxes

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes as a result of the following ($ in thousands):


	Years Ended December 31,
	2020		2019
U.S. Federal benefit at statutory rate	$	(3,993)	$	(4,064)
State and local (benefit) / expense net of U.S. federal tax	—		—
Permanent non deductible expenses for U.S. taxes	5		14
AMT credit benefit	—		—
Change in state deferred	5,122		(4,720)
Return to actual	—		(17)
Other true ups	387		1,941
Effect of change in deferred tax rate	—		—
Sale of New Jersey State NOL's	(10,872)		—
Valuation allowance for deferred tax assets	(1,521)		6,846
Tax provision (benefit)	$	(10,872)	$	—

Schedule of Components Deferred Income Taxes

Deferred income taxes at December 31, 2020 and 2019 consist of the following ($ in thousands):


	December 31,
	2020		2019
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	68,286	$	70,747
CIRM funding	—		336

Right of use liability	176		205
Share-based compensation	5,025		3,584
Intangibles	131		141




Accumulated depreciation	19		9
Accrued payroll	167		121

Other	526		737
Deferred tax assets	74,330		75,880

Deferred Tax Liabilities:
Right of use asset	$	(161)	$	(190)

Deferred tax liabilities	(161)		(190)
	74,169		75,690
Valuation allowance	(74,169)		(75,690)
Net deferred tax asset	$	—	$	—

Summary of Significant Accounting Policies (Details)	12 Months Ended
Summary of Significant Accounting Policies (Details)	Dec. 31, 2020
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Software
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years

Available-for-Sale-Securities - Summary (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Cost	$ 30,750	$ 22,766
Gross Unrealized Gains	0	3
Gross Unrealized Losses	(13)	(1)
Estimated Fair Value	30,737	22,768
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Cost	8,406	11,673
Gross Unrealized Gains	0	3
Gross Unrealized Losses	(7)	(1)
Estimated Fair Value	8,399	11,675
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	7,591	11,093
Gross Unrealized Gains	0
Gross Unrealized Losses
Estimated Fair Value	7,591	11,093
Municipal debt securities
Debt Securities, Available-for-sale [Line Items]
Cost	14,753	0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(6)	0
Estimated Fair Value	$ 14,747	$ 0

Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Available-for-sale debt securities	$ 30,737	$ 22,768
Cash and cash equivalents
Debt Securities, Available-for-sale [Line Items]
Available-for-sale debt securities	12,676	11,643
Marketable securities
Debt Securities, Available-for-sale [Line Items]
Available-for-sale debt securities	$ 18,061	$ 11,125

Available-for-Sale-Securities - Contractual Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Amortized Cost
Less than one year	$ 30,750	$ 22,766
Greater than one year	0	0
Cost	30,750	22,766
Estimated Fair Value
Less than one year	30,737	22,768
Greater than one year	0	0
Estimated fair value	$ 30,737	$ 22,768

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 100	$ 100
Property, Plant and Equipment [Line Items]
Property and equipment, gross	370	349
Accumulated depreciation	(313)	(249)
Property and equipment, net	57	100
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	26	26
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	254	247
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 90	$ 76

Loss Per Share (Details) - shares shares in Thousands	12 Months Ended
Loss Per Share (Details) - shares shares in Thousands	Dec. 31, 2020	Dec. 31, 2019
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of loss per share	964	1,044
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of loss per share	2,638	30
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of loss per share	340	118

Fair Value Measurements (Details) - Recurring - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets:
Marketable securities - available for sale	$ 18,061	$ 11,125
Assets - fair value	18,061	11,125
Level 1
Assets:
Marketable securities - available for sale	0	0
Assets - fair value	0	0
Level 2
Assets:
Marketable securities - available for sale	18,061	11,125
Assets - fair value	18,061	11,125
Level 3
Assets:
Marketable securities - available for sale	0	0
Assets - fair value	$ 0	$ 0

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 1,716	$ 1,834
Operating lease liabilities - current	370	354
CIRM upfront funding - current	0	1,600
Other	400	698
Accrued liabilities	$ 2,486	$ 4,486

Operating Leases - Narrative (Details)	Dec. 31, 2020
Leases [Abstract]
Weighted average remaining lease term for operating leases (in years)	1 year 9 months 29 days
Weighted average discount rate for operating leases (percent)	9.625%

Operating Leases - Balance Sheet Presentation (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet
Right-of-use assets	$ 574	$ 906
Operating lease liabilities, current	370	354
Operating lease liabilities	$ 624	$ 977
Right-of-use asset, balance sheet line item	us-gaap:OtherAssets	us-gaap:OtherAssets
Operating lease liabilities, current, balance sheet line item	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent	us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
Operating lease liabilities, noncurrent, balance sheet line item	us-gaap:OtherLiabilitiesNoncurrent	us-gaap:OtherLiabilitiesNoncurrent
Other assets
Balance Sheet
Right-of-use assets	$ 574	$ 906
Accrued liabilities
Balance Sheet
Operating lease liabilities, current	370	353
Other long-term liabilities
Balance Sheet
Operating lease liabilities, noncurrent	$ 254	$ 624

Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Future Minimum Lease Payments
2021	$ 414,000
2022	239,000
2023	26,000
Total lease payments	679,000
Less: Amounts representing interest	(55,000)
Present value of lease liabilities	$ 624,000	$ 977,000

Stockholders' Equity - Equity Plan (Details)	12 Months Ended
Stockholders' Equity - Equity Plan (Details)	Dec. 31, 2020 USD ($) offering_period shares	Jun. 30, 2019 shares	May 31, 2017 shares	Jan. 01, 2013 shares
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance	2,500,000
Number of shares available for future grant	1,376,030
2018 Plan \| Stock Options \| Share-based award tranche one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)	2 years
2018 Plan \| Stock Options \| Share-based award tranche two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)	3 years
2018 Plan \| Stock Options \| Share-based award tranche three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period (in years)	10 years
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of offering periods \| offering_period	2
Term of offering period	6 months
Maximum annual contribution per employee as percent of annual salary	15.00%
Maximum annual contribution per employee \| $	$ 25,000
Purchase price measurement as percent of closing price on enrollment date	85.00%
Purchase price measurement as percent of closing price on exercise date	85.00%
2012 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance				50,000
2017 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance			100,000
Amended 2017 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance		500,000
Number of shares available for future grant	347,709
Shares issued under ESPP	32,137

Stockholders' Equity - Equity Issuances (Details) - USD ($)		1 Months Ended				12 Months Ended	35 Months Ended
	Jul. 10, 2020	May 31, 2020	Apr. 30, 2020	Mar. 31, 2019	Aug. 31, 2018	Dec. 31, 2020	Dec. 31, 2020	Feb. 28, 2018
Lincoln Park Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement				$ 26,000,000.0
Commitment shares issued as consideration per agreement (shares)				181,510
Number of shares sold (shares)				250,000
Price of shares sold (in dollars per share)				$ 4.00
Gross price for stock transaction				$ 1,000,000
Term of agreement (in months)				36 months
Number of shares allowable to direct for Regular Purchase (shares)				100,000
Maximum obligation per directed purchase transaction for Regular Purchase				$ 2,500,000
Maximum shares allowed in Accelerated Purchase as percent of shares in Regular Purchase (percent)				300.00%
Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)				30.00%
Maximum beneficial ownership allowable per agreement (percent)				9.99%
H.C. Wainwright Sales Amended Agreement
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement				$ 17,600,000	$ 25,000,000.0			$ 25,000,000.0
Aggregate market value of common stock held by non-affiliates				$ 52,800,000
Maximum number of shares authorized per agreement (shares)				4,800,000
Commission on gross proceeds due to third party (percent)					3.00%
Stock issued (shares)						3,558,778	3,784,912
Proceeds from issuance of stock						$ 8,500,000	$ 9,500,000
April Purchase Agreement
Class of Stock [Line Items]
Number of shares sold (shares)			2,162,166
Price of shares sold (in dollars per share)			$ 2.3125
Number of shares called by warrants issued			1,081,083
Proceeds from issuance of stock			$ 5,000,000.0
Number of shares per each warrant			1
Warrant exercise price (in dollars per share)			$ 2.2500
Warrants expiration term			5 years 6 months
May Purchase Agreement
Class of Stock [Line Items]
Number of shares sold (shares)		2,084,850
Price of shares sold (in dollars per share)		$ 2.0625
Number of shares called by warrants issued		1,042,425
Proceeds from issuance of stock		$ 4,300,000
Number of shares per each warrant		1
Warrant exercise price (in dollars per share)		$ 2.0625
Warrants expiration term		5 years 6 months
July 2020 Private Placement
Class of Stock [Line Items]
Number of shares sold (shares)	969,694
Price of shares sold (in dollars per share)	$ 2.0625
Number of shares called by warrants issued	484,847
Proceeds from issuance of stock	$ 2,000,000.0
Number of shares per each warrant	1
Warrant exercise price (in dollars per share)	$ 2.0625
Warrants expiration term	5 years 6 months

Stockholders' Equity - Stock Options and Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock Options, Shares
Outstanding, beginning balance (shares)	1,044,417
Granted (shares)	248,176
Exercised (shares)	0
Forfeited (shares)	(86,251)
Expired (shares)	(242,642)
Outstanding, ending balance (shares)	963,700	1,044,417
Vested or expected to vest (shares)	949,200
Exercisable (shares)	714,426
Stock Options, Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 18.31
Granted (in dollars per share)	3.20
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	3.83
Expired (in dollars per share)	22.57
Outstanding, ending balance (in dollars per share)	14.64	$ 18.31
Vested or expected to vest (in dollars per share)	14.81
Exercisable (in dollars per share)	$ 18.42
Stock Options, Weighted Average Contractual Term and Intrinsic Value
Stock options outstanding, weighted average remaining contractual term (in years)	5 years 10 months 9 days	6 years 21 days
Stock options vested or expected to vest, weighted average remaining contractual term (in years)	5 years 9 months 25 days
Stock options exercisable, weighted average remaining contractual term (in years)	4 years 11 months 4 days
Stock options outstanding, aggregate intrinsic value	$ 0	$ 0
Stock options exercisable, aggregate intrinsic value	0
Stock options vested or expected to vest, aggregate intrinsic value	$ 0
Warrants, Shares
Warrants outstanding, beginning balance (shares)	30,000
Warrants granted (shares)	2,608,355
Warrants exercised (shares)	0
Warrants forfeited (shares)	0
Warrants expired (shares)	0
Warrants outstanding, ending balance (shares)	2,638,355	30,000
Warrants vested or expected to vest (shares)	2,638,355
Warrants exercisable (shares)	2,638,355
Warrants, Weighted Average Exercise Price
Warrants outstanding, beginning balance (in dollars per share)	$ 5.89
Warrants granted (in dollars per share)	2.14
Warrants exercised (in dollars per share)	0
Warrants forfeited (in dollars per share)	0
Warrants expired (in dollars per share)	0
Warrants outstanding, ending balance (in dollars per share)	2.18	$ 5.89
Warrants vested or expected to vest (in dollars per share)	2.18
Warrants exercisable (in dollars per share)	$ 2.18
Warrants, Weighted Average Contractual Term and Intrinsic Value
Warrants outstanding, weighted average remaining contractual term (in years)	4 years 11 months 23 days	3 years 2 months 8 days
Warrants vested or expected to vest, weighted average remaining contractual term (in years)	4 years 11 months 23 days
Warrants exercisable, weighted average remaining contractual term (in years)	4 years 11 months 23 days
Warrants outstanding, aggregate intrinsic value	$ 0	$ 0
Warrants vested or expected to vest, aggregate intrinsic value	0
Warrants exercisable, aggregate intrinsic value	$ 0

Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock
Restricted Stock and Restricted Stock Units
Number of shares issued (shares)	156,184	123,564
Value of shares issued	$ 512,300	$ 611,600
Weighted average estimated fair value	$ 3.28	$ 4.95
Restricted Stock \| Minimum
Restricted Stock and Restricted Stock Units
Vesting terms (in years)	1 year
Restricted Stock \| Maximum
Restricted Stock and Restricted Stock Units
Vesting terms (in years)	4 years
Restricted Stock Units
Restricted Stock and Restricted Stock Units
Number of shares issued (shares)	325,853	184,454
Value of shares issued	$ 863,000.0	$ 908,600
Weighted average estimated fair value	$ 2.65	$ 4.93
Vesting terms (in years)	1 year

Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation [Line Items]
Share-based compensation expense	$ 1,265	$ 1,295
Research and development
Share-based Compensation [Line Items]
Share-based compensation expense	179	274
General and administrative
Share-based Compensation [Line Items]
Share-based compensation expense	$ 1,086	$ 1,021

Share-Based Compensation - Compensation Cost Not Yet Recognized (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 356
Expected weighted-average period in years of compensation cost to be recognized	1 year 7 months 9 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 244
Expected weighted-average period in years of compensation cost to be recognized	2 years 5 months 15 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 308
Expected weighted-average period in years of compensation cost to be recognized	1 year 7 months 24 days

Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 536	$ 398
Weighted average estimated fair value of shares granted (in dollars per share)	$ 2.11	$ 3.18

Share-Based Compensation - Valuation Assumptions (Details) - Stock Options	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Valuation Assumptions
Expected volatility - minimum	75.00%	74.00%
Expected volatility - maximum	79.00%	74.00%
Weighted Average volatility	75.00%	74.00%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate - minimum	0.40%	2.35%
Risk-free interest rate - maximum	1.71%	2.62%
Minimum
Valuation Assumptions
Expected term (in years)	6 years	6 years
Maximum
Valuation Assumptions
Expected term (in years)	6 years	6 years

Research Funding (Details) - USD ($) $ in Thousands	1 Months Ended					12 Months Ended		44 Months Ended
Research Funding (Details) - USD ($) $ in Thousands	Sep. 30, 2020	May 31, 2019	Mar. 31, 2018	Dec. 31, 2017	May 31, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Feb. 28, 2017
Research and Development [Abstract]
Grants awarded						$ 8,600		$ 8,600	$ 12,200
Funding of grant award					$ 5,700			$ 8,200
Milestone payment received on grant award				$ 1,900
Progress payment received on grant award			$ 300
Progress payment amortized to related research and development over estimated award period	$ 46	$ 200
Amortization of accrued grant funding to offset expense						$ 1,600	$ 2,700

Income Taxes - Narrative (Details) - USD ($) $ in Millions		12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Apr. 21, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
U.S. federal corporate income tax rate (percent)		21.00%
Market capitalization used in net operating loss analysis		$ 125.0
Annual limitation on usage of net operating losses		3.0
Sale Of Net Operating Losses, NJEDA Program, Value	$ 11.5
Proceeds From Sale Of Net Operating Losses, NJEDA Program	$ 10.9
Federal
Income Taxes [Line Items]
Net operating loss carryforwards		264.0	$ 246.0
State \| New Jersey
Income Taxes [Line Items]
Net operating loss carryforwards		99.0	187.0
State \| California
Income Taxes [Line Items]
Net operating loss carryforwards		70.0	70.0
State \| New York
Income Taxes [Line Items]
Net operating loss carryforwards		$ 13.0	$ 13.0

Income Taxes - Loss from Operations Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Pre-tax book income - United States	$ (19,013)	$ (19,352)
Pre-tax book income	$ (19,013)	$ (19,352)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Components of Benefit from Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Current
U.S. Federal	$ 0	$ 0
State and local	0	0
Total current income tax provision (benefit)	0	0
Deferred
U.S. Federal	0	0
State and local	(10,872)	0
Total deferred income tax provision (benefit)	(10,872)	0
Total
U.S. Federal	0	0
State and local	(10,872)	0
Tax provision (benefit)	$ (10,872)	$ 0

Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]
U.S. Federal benefit at statutory rate	$ (3,993,000)	$ (4,064,000)
State and local (benefit) / expense net of U.S. federal tax	0	0
Permanent non deductible expenses for U.S. taxes	5,000	14,000
AMT credit benefit	0	0
Change in state deferred	5,122,000	(4,720,000)
Return to actual	0	(17,000)
Other true ups	387,000	1,941,000
Effect of change in deferred tax rate	0	0
Sale of New Jersey State NOL's	(10,872,000)	0
Valuation allowance for deferred tax assets	(1,521,000)	6,846,000
Tax provision (benefit)	$ (10,872,000)	$ 0

Income Taxes - Components of Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$ 68,286	$ 70,747
CIRM funding	0	336
Right of use liability	176	205
Share-based compensation	5,025	3,584
Intangibles	131	141
Accumulated depreciation	19	9
Accrued payroll	167	121
Other	526	737
Deferred tax assets	74,330	75,880
Deferred Tax Liabilities:
Right of use asset	(161)	(190)
Deferred tax liabilities	(161)	(190)
Net deferred tax assets and liabilities	74,169	75,690
Valuation allowance	(74,169)	(75,690)
Net deferred tax asset	$ 0	$ 0

Subsequent Events (Details) - USD ($)			2 Months Ended	12 Months Ended	35 Months Ended	36 Months Ended
Subsequent Events (Details) - USD ($)	Feb. 12, 2021	Jan. 21, 2021	Feb. 25, 2021	Dec. 31, 2020	Dec. 31, 2020	Feb. 12, 2021	Mar. 31, 2019	Aug. 31, 2018	Feb. 28, 2018
Subsequent event
Subsequent Event [Line Items]
Proceeds from issuance of stock	$ 60,700,000
Shares issued upon exercise of warrants			801,148
Net proceeds from warrant exercises			$ 1,800,000
Institutional Purchase Agreement \| Subsequent event
Subsequent Event [Line Items]
Number of shares sold (shares)	24,906,134
Price of shares sold (in dollars per share)	$ 2.45					$ 2.45
Number of shares called by warrants issued	12,453,067					12,453,067
Warrant exercise price (in dollars per share)	$ 2.90					$ 2.90
Warrants expiration term	5 years					5 years
Additional Purchase Agreement \| Subsequent event
Subsequent Event [Line Items]
Number of shares sold (shares)	1,632,652
Price of shares sold (in dollars per share)	$ 2.45					$ 2.45
Number of shares called by warrants issued	816,326					816,326
Warrant exercise price (in dollars per share)	$ 2.90					$ 2.90
Warrants expiration term	5 years					5 years
January 2021 Private Placement \| Subsequent event
Subsequent Event [Line Items]
Number of shares sold (shares)		12,500,000
Price of shares sold (in dollars per share)		$ 2.00
Number of shares called by warrants issued		6,250,000
Proceeds from issuance of stock		$ 25,000,000.0
Number of shares per each warrant		1
Warrant exercise price (in dollars per share)		$ 2.90
Warrants expiration term		5 years 6 months
H.C. Wainwright Sales Amended Agreement
Subsequent Event [Line Items]
Proceeds from issuance of stock				$ 8,500,000	$ 9,500,000
Aggregate offering amount authorized per agreement							$ 17,600,000	$ 25,000,000.0	$ 25,000,000.0
Stock issued (shares)				3,558,778	3,784,912
H.C. Wainwright Sales Amended Agreement \| Subsequent event
Subsequent Event [Line Items]
Proceeds from issuance of stock						$ 9,500,000
Stock issued (shares)						3,784,912